Opko Health Inc (OPK)

$1.28 0.00 (N/A)
Market Cap 982.66M
Revenue (ttm) 713.14M
Net Income (ttm) -53.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7.46%
Debt to Equity Ratio 0.19
Volume 2,636,500
Avg Vol 2,305,750
Day's Range N/A - N/A
Shares Out 767.70M
Stochastic %K 30%
Beta 1.50
Analysts Strong Sell
Price Target $2.57

Company Profile

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 305 575 4100
Address:
4400 Biscayne Boulevard, Miami, United States
Sierradude
Sierradude Nov. 14 at 3:00 PM
$OPK His salary is 1.4M a year.....why, I have no idea
0 · Reply
Mike18181
Mike18181 Nov. 14 at 1:39 PM
$OPK BUY shares in Opko there doing so many great things ... EPS is almost here IMO . Adam Logal should get a big raise and bonus for Being a great CFO
0 · Reply
tymtested
tymtested Nov. 13 at 11:30 PM
$OPK Frosts net worth $2.1B but his OPKO holdings are about $325M.
0 · Reply
tymtested
tymtested Nov. 13 at 11:23 PM
$OPK wonder how he gained $200M in 2025.
0 · Reply
tymtested
tymtested Nov. 13 at 11:22 PM
$OPK Ole #1873 https://www.forbes.com/profile/phillip-frost/
0 · Reply
tymtested
tymtested Nov. 13 at 11:18 PM
$OPK whoever will be managing Frost's shares will definitely be in the driver's seat. Frost is destined to live to 120.
0 · Reply
Sierradude
Sierradude Nov. 13 at 10:44 PM
$OPK Will be truly interesting to see if it gets a pop upon Frostys "departure".
0 · Reply
Brasil07
Brasil07 Nov. 13 at 8:57 PM
$OPK must die, must die, One day Frosty must die....
0 · Reply
tymtested
tymtested Nov. 13 at 4:49 PM
$OPK LOL.. just put in a buy order and it clicked up...
1 · Reply
tymtested
tymtested Nov. 13 at 4:44 PM
$OPK analysts have taken a critical view of opko because of a reduction in revenues. They dont even slightly recognize that OPKO sold off the loss making part of the lab business. And the money coming from Ngenla is all earnings!!! Royalties!! If OPKO was receiving revenues for the NGENLA earnings, there would be a significant increase!! just tell me Im wrong!!??!!??!
0 · Reply
Latest News on OPK
OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 9:36 PM EDT - 16 days ago

OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

Oct 29, 2025, 4:05 PM EDT - 16 days ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Oct 22, 2025, 4:05 PM EDT - 23 days ago

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Sep 15, 2025, 8:30 AM EDT - 2 months ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

LH

OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:19 PM EDT - 3 months ago

OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

Jul 31, 2025, 4:05 PM EDT - 3 months ago

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

NextPlat Issues Interim CEO Update Shareholder Letter

Jun 30, 2025, 8:01 AM EDT - 4 months ago

NextPlat Issues Interim CEO Update Shareholder Letter

NXPL

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

Jun 25, 2025, 11:00 AM EDT - 5 months ago

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

OPKO Health to Participate in Two Upcoming Investor Conferences

May 15, 2025, 8:00 AM EDT - 6 months ago

OPKO Health to Participate in Two Upcoming Investor Conferences

OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 7:52 PM EDT - 7 months ago

OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Apr 4, 2025, 8:00 AM EDT - 8 months ago

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

OPKO and Entera partner to develop obesity pill

Mar 17, 2025, 8:57 AM EDT - 8 months ago

OPKO and Entera partner to develop obesity pill

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Mar 11, 2025, 7:00 AM EDT - 8 months ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

LH

OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:12 PM EST - 9 months ago

OPKO Health, Inc. (OPK) Q4 2024 Earnings Call Transcript

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

Feb 27, 2025, 4:10 PM EST - 9 months ago

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 11:45 AM EST - 11 months ago

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

Nov 18, 2024, 8:00 AM EST - 1 year ago

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

NXPL

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

Nov 14, 2024, 6:00 AM EST - 1 year ago

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

BABA NXPL

OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 8:30 PM EST - 1 year ago

OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

Oct 7, 2024, 8:00 AM EDT - 1 year ago

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

NXPL

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

LH

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 7, 2024, 4:06 PM EDT - 1 year ago

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

Jul 17, 2024, 4:14 PM EDT - 1 year ago

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

OPKO Health to Participate in the Jefferies Global Healthcare Conference

May 31, 2024, 10:48 AM EDT - 1 year ago

OPKO Health to Participate in the Jefferies Global Healthcare Conference

OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript

May 7, 2024, 8:03 PM EDT - 1 year ago

OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

May 7, 2024, 4:05 PM EDT - 1 year ago

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

May 3, 2024, 8:00 AM EDT - 1 year ago

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

LH

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Mar 5, 2024, 8:52 AM EST - 1 year ago

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 8:08 PM EST - 1 year ago

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Feb 27, 2024, 4:05 PM EST - 1 year ago

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Feb 22, 2024, 4:05 PM EST - 1 year ago

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

Jan 9, 2024, 4:05 PM EST - 2 years ago

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Jan 4, 2024, 11:31 PM EST - 2 years ago

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Jan 3, 2024, 5:05 PM EST - 2 years ago

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Nov 28, 2023, 7:00 AM EST - 2 years ago

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Nov 7, 2023, 6:45 AM EST - 2 years ago

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

SOPH

OPKO Health, Inc. (OPK) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 7:32 PM EST - 2 years ago

OPKO Health, Inc. (OPK) Q3 2023 Earnings Call Transcript

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 6, 2023, 4:05 PM EST - 2 years ago

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Nov 2, 2023, 10:00 AM EDT - 2 years ago

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Oct 25, 2023, 4:25 PM EDT - 2 years ago

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

OPKO Health: FDA Approval To Save The Company

Oct 20, 2023, 1:30 PM EDT - 2 years ago

OPKO Health: FDA Approval To Save The Company

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Sep 28, 2023, 4:08 PM EDT - 2 years ago

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript

Aug 4, 2023, 12:17 AM EDT - 2 years ago

OPKO Health, Inc. (OPK) Q2 2023 Earnings Call Transcript

OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 Earnings

Jul 31, 2023, 2:19 PM EDT - 2 years ago

OPKO Health: Improving Profitability Should Drive Shares Forward Post Q2 Earnings

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

Jul 25, 2023, 4:05 PM EDT - 2 years ago

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

Jun 28, 2023, 6:45 AM EDT - 2 years ago

FDA Approves Pfizer's NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

PFE

OPKO Health's Future After Merck Deal: Bright Or Uncertain

May 11, 2023, 12:29 PM EDT - 2 years ago

OPKO Health's Future After Merck Deal: Bright Or Uncertain

MRK

Sierradude
Sierradude Nov. 14 at 3:00 PM
$OPK His salary is 1.4M a year.....why, I have no idea
0 · Reply
Mike18181
Mike18181 Nov. 14 at 1:39 PM
$OPK BUY shares in Opko there doing so many great things ... EPS is almost here IMO . Adam Logal should get a big raise and bonus for Being a great CFO
0 · Reply
tymtested
tymtested Nov. 13 at 11:30 PM
$OPK Frosts net worth $2.1B but his OPKO holdings are about $325M.
0 · Reply
tymtested
tymtested Nov. 13 at 11:23 PM
$OPK wonder how he gained $200M in 2025.
0 · Reply
tymtested
tymtested Nov. 13 at 11:22 PM
$OPK Ole #1873 https://www.forbes.com/profile/phillip-frost/
0 · Reply
tymtested
tymtested Nov. 13 at 11:18 PM
$OPK whoever will be managing Frost's shares will definitely be in the driver's seat. Frost is destined to live to 120.
0 · Reply
Sierradude
Sierradude Nov. 13 at 10:44 PM
$OPK Will be truly interesting to see if it gets a pop upon Frostys "departure".
0 · Reply
Brasil07
Brasil07 Nov. 13 at 8:57 PM
$OPK must die, must die, One day Frosty must die....
0 · Reply
tymtested
tymtested Nov. 13 at 4:49 PM
$OPK LOL.. just put in a buy order and it clicked up...
1 · Reply
tymtested
tymtested Nov. 13 at 4:44 PM
$OPK analysts have taken a critical view of opko because of a reduction in revenues. They dont even slightly recognize that OPKO sold off the loss making part of the lab business. And the money coming from Ngenla is all earnings!!! Royalties!! If OPKO was receiving revenues for the NGENLA earnings, there would be a significant increase!! just tell me Im wrong!!??!!??!
0 · Reply
tymtested
tymtested Nov. 13 at 4:39 PM
$OPK While the market is irrationally taking the stock down, it really works to the benefit of the stock buyback program is a Huge way!! GO OPKO! analysts have no clue.
0 · Reply
steviem
steviem Nov. 13 at 3:56 PM
$OPK The IBB is up 24% year to date and OPK is down 12%.....can you say pathetic???
1 · Reply
TommyCotton
TommyCotton Nov. 13 at 12:52 AM
$OPK place no confidence in insider buying—specifically Frost buying. He’s done this for the past decade. Why? No one knows but him and it doesn’t make a bit of sense and has nothing to do with the value of the stock.
1 · Reply
tymtested
tymtested Nov. 12 at 7:15 PM
$OPK The amount by which OPKO is undervalued or the market hates Frost can be seen in these numbers. OPKO mc is $1.02B. At a realistic PE of 30, earnings need only be $35M. Ngenla alone generates that in 2026 by conservative estimates. Now layer on all the other income streams and pipe potential. OPKO is bound to explode upward at some point. Huge bucks are still being spent in R&D, so R&D needs to produce something.
2 · Reply
tradertrash
tradertrash Nov. 12 at 3:40 PM
$OPK 200MM per molecule, then run it back thru r&d, dont deliver for sh, b sure mgt gets raises&bonuses rinse&repeat
0 · Reply
tradertrash
tradertrash Nov. 12 at 3:31 PM
$OPK just a big r&d skam that never delivers for shareholders
0 · Reply
LongAllDay
LongAllDay Nov. 12 at 2:48 PM
$OPK still on track
0 · Reply
tymtested
tymtested Nov. 12 at 2:10 PM
$OPK stop loss raids are only executed in stocks that are truly highly undervalued. Otherwise, whats the point.
0 · Reply
Mike18181
Mike18181 Nov. 12 at 2:09 PM
$OPK What are Forward looking statements ? We anticipate 200million per molecule up to a Billion dollars, we expect to have BRL profitable, So, what actually was reality for shareholders. 1.30 per shares tells you what goes on behind the curtain !! Fact !
0 · Reply
tymtested
tymtested Nov. 12 at 1:23 PM
$OPK investors who got stopped out yesterday are going to be faced with having to buy back in at a higher price. Whoever executed that stop loss raid yesterday is clearly highly convinced the stock is headed up. Many investors were stopped out . Im still in and holding.
0 · Reply
tymtested
tymtested Nov. 12 at 12:35 PM
$OPK opko is headed UP!
0 · Reply
magadog
magadog Nov. 12 at 12:21 PM
$OPK FROST / BIDEN a distinction without a difference.
0 · Reply